腦生物標記市場報告：2031 年趨勢、預測與競爭分析

全球腦生物標記市場前景光明，醫院、研究實驗室、門診手術中心和診斷實驗室市場都存在機會。預計到 2031 年，全球腦生物標記市場規模將達到 180 億美元，2025 年至 2031 年的複合年成長率為 7.4%。該市場的主要驅動力是對神經系統疾病精準診斷技術的需求不斷成長，對有助於早期發現和管理心理健康問題的生物標記的需求不斷成長，以及對個性化醫療的需求不斷成長，其中腦生物標記可用於為神經系統疾病患者制定個性化治療計劃。

• 根據產品類型，Lucintel 預測生物標記檢測套組在預測期內仍將佔據很大佔有率，因為它們在診斷和研究中發揮關鍵作用，為識別和量化與各種神經系統疾病相關的生物標記提供了可靠有效的技術。
• 根據最終用途，生物標記將繼續成為最大的細分市場，因為醫院將其用於各種目的，例如早期疾病識別和治療監測，從而實現及時干預和客製化治療方法。
• 根據地區，預計北美在預測期內仍將是最大的地區。

腦生物標記市場的策略性成長機會

由於研究和技術的進步以及神經系統疾病盛行率的上升，腦生物標記市場正在出現多種策略性成長機會。

• 阿茲海默症的早期診斷：對阿茲海默症早期診斷工具的需求正在創造巨大的成長機會。生物標記有助於早期診斷，從而及時介入並改善患者的治療效果。
• 推進治療選擇：向個人化醫療的轉變為生物標記指導治療鋪平了道路。根據特定的生物標記譜開發治療方法可以實現更有效、更有針對性的治療，同時降低副作用的風險。
• 投資神經退化性疾病研究：人們對帕金森氏症和多發性硬化症等疾病的興趣日益濃厚，推動了對腦生物標記研究的投資。在這些領域發現的新生物標記可以幫助更有效地診斷和監測這些疾病。
• 研究合作：學術界、研究機構和產業相關人員之間加強合作正在加速生物標記的發現和應用。這樣的夥伴關係有助於縮短研究時間並更快地將新的診斷工具推向市場。
• 擴大臨床應用：在臨床實踐中應用生物標記的需求日益增加。隨著生物標記被檢驗具有更廣泛的用途，它們在各種神經系統疾病的診斷和管理中應用的機會可能會增加。

這些機會凸顯了腦生物標記市場持續成長的潛力，為神經病學領域的新發現和加強患者照護提供了途徑。

腦生物標記市場促進因素與挑戰

腦生物標記產品的商業化受到許多促進因素和挑戰的影響，包括現有技術、社會經濟和法規環境。為了在市場中營運，了解這些動態非常重要。

推動腦生物標記市場發展的因素有：

• 技術進步：生物標記檢測及其分析的原理、方法和手段的持續技術改進確保了市場的成長。新的識別技術和診斷技術、基因組學和蛋白​​質組學技術的發展將提高診斷的敏感性和特異性。
• 增加研究經費：分配給神經科學和神經系統疾病研究的投資不斷增加，推動了腦生物標記的成長。臨床試驗資金籌措通常相當可觀，津貼和促進可帶來有效決策的檢驗過程。
• 神經系統疾病發生率上升：阿茲海默症和帕金森氏症新患者不斷增加，需要有效的診斷解決方案。在這些情況下，生物標記可以幫助臨床檢測和監測病情。
• 基於生物標記的檢測需求不斷增加：個人化醫療的興起帶來了基於生物標記的診斷需求。腫瘤學作為臨床實踐受益於生物標記，因為針對特定患者需求量身定做的治療方法可以改善臨床結果。
• 津貼申請的合作支援：透過與學術界、工業界和臨床合作夥伴的有效合作，並行發明支持腦生物標記開發工作。這種合作促進了資源共用並有助於加快進展。

腦生物標記市場面臨的挑戰是：

• 監管障礙：獲得基於生物標記的診斷設備的核准既費時又昂貴。漫長的核准過程可能會延遲向需要的患者提供新的診斷工具。
• 財務障礙：開發和檢驗腦生物標記的成本很高，這帶來了挑戰，尤其是對於資金有限的小公司。這可能會減緩進展並限制獲得創新解決方案的機會。
• 市場競爭：隨著越來越多的公司進入腦生物標記市場，競爭日益激烈。為了保持競爭力並獲得市場佔有率，企業必須使其產品和服務與眾不同。

克服市場促進因素和挑戰將是腦生物標記領域成功的關鍵。

每個新興國家都在為腦生物標記的發展做出重大貢獻，致力於提高神經系統疾病的診斷準確性和治療性介入。

目錄

第1章執行摘要

第2章全球腦生物標記市場：市場動態

• 簡介、背景和分類
• 供應鏈
• 產業驅動力與挑戰

第3章 2019年至2031年市場趨勢及預測分析

• 宏觀經濟趨勢（2019-2024）及預測（2025-2031）
• 全球腦生物標記市場趨勢（2019-2024）及預測（2025-2031）
• 全球腦生物標記市場（依產品類型）
  • 生物標記檢測套組
  • 生物標記分析裝置
• 全球腦生物標記市場（按疾病適應症）
  • 中風
  • 肌萎縮側索硬化症和肌萎縮側索硬化症
  • 阿茲海默症和其他失智症
  • 帕金森氏症
  • 亨丁頓舞蹈症
• 按應用：全球腦生物標記市場
  • 診斷
  • 藥物研發
  • 其他
• 全球腦生物標記市場（按最終用途）
  • 醫院
  • 研究部門
  • 門診手術中心
  • 診斷實驗室
  • 其他

第4章2019年至2031年區域市場趨勢與預測分析

• 按地區分類：全球腦生物標記市場
• 北美腦生物標記市場
• 歐洲腦生物標記市場
• 亞太腦生物標記市場
• 世界其他地區腦生物標記市場

第5章 競爭分析

• 產品系列分析
• 業務整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球腦生物標記市場成長機會（按產品類型）
  • 全球腦生物標記市場成長機會（依疾病指徵）
  • 全球腦生物標記市場成長機會（按應用）
  • 全球腦生物標記市場成長機會（依最終用途）
  • 全球腦生物標記市場各區域成長機會
• 全球腦生物標記市場的新趨勢
• 戰略分析
  • 新產品開發
  • 全球腦生物標記市場容量不斷擴大
  • 全球腦生物標記市場的合併、收購和合資企業
  • 認證和許可

第7章主要企業簡介

• Siemens Healthineers
• Electrical Geodesics
• Lifesign
• Advanced Brain Monitoring
• BrainScope
• GE Healthcare
• Johnson & Johnson
• Natus Medical
• F. Hoffmann-La Roche
• Qiagen

The future of the global brain biomarker market looks promising with opportunities in the hospital, research laboratory, ambulatory surgical center, and diagnostic laboratory markets. The global brain biomarker market is expected to reach an estimated $18 billion by 2031 with a CAGR of 7.4% from 2025 to 2031. The major drivers for this market are the increased need for precise diagnostic techniques in neurological diseases, the rising need for biomarkers to aid in the early identification and management of mental health issues, and the growing demand for personalized medicine, brain biomarkers can be used to develop personalized treatment plans for patients with neurological disorders.

• Lucintel forecasts that, within the product type category, biomarker test kit will remain the larger segment over the forecast period due to their critical role in diagnostics and research, offering a reliable and effective technique to identify and quantify biomarkers linked with diverse neurological disorders.
• Within the end use category, hospitals will remain the largest segment due to hospitals use biomarkers for a variety of objectives, including early illness identification and treatment monitoring, which allows for prompt interventions and tailored care regimens.
• In terms of regions, North America will remain the largest region over the forecast period.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Brain Biomarker Market

The brain biomarker market is undergoing significant transformation driven by technological advancements, research funding, and the growing emphasis on personalized medicine. These trends are reshaping the way neurological disorders are diagnosed, monitored, and treated.

• AI and Machine Learning Integration: Artificial intelligence (AI) and machine learning are revolutionizing the brain biomarker field by analyzing complex datasets more efficiently. These technologies enhance the discovery of new biomarkers and improve the predictive accuracy of existing ones, simplifying diagnosis and treatment plans.
• Personalized Medicine Approach: Personalized medicine is gaining traction in the brain biomarker market, with treatments increasingly tailored to individual biomarker profiles. By leveraging genetic profiling and biomarker analysis, healthcare providers can customize treatments to improve patient outcomes and minimize adverse effects.
• Increased Investment in Research: Growing funding from both public and private sectors is fueling research into neurological diseases, leading to the discovery of new biomarkers. This investment is critical for early detection, more accurate diagnosis, and more effective treatments.
• Collaboration Between Sectors: Enhanced collaboration between academia, industry, and healthcare organizations is accelerating biomarker development. These partnerships facilitate the transfer of knowledge and resources, leading to faster development and implementation of biomarker-based diagnostics and treatments.
• Regulatory Advancements: Regulatory landscapes are evolving, particularly in Western countries, where there is a growing push to incorporate biomarkers into clinical applications. Relaxation of market access barriers is helping to expedite the use of biomarkers in clinical practice.

These trends are significantly impacting the brain biomarker market, improving both the speed and accuracy of diagnosis and leading to more effective therapeutic interventions for neurological diseases.

Recent Developments in the Brain Biomarker Market

Recent advancements in the brain biomarker market are a result of ongoing technological progress and increased research efforts, particularly in the areas of biomarker discovery, validation, and clinical application.

• FDA Approvals for Novel Biomarkers: Recent FDA approvals of blood-based biomarkers for Alzheimer's disease have opened up new avenues for early detection and treatment. These innovations offer the potential for earlier interventions and more targeted therapeutic strategies.
• AI-Based Biomarker Discovery: The integration of AI in the biomarker discovery process is transforming how large datasets, including genetic and neuroimaging data, are analyzed. AI-driven approaches can identify novel biomarkers with higher predictive potential, enabling earlier diagnosis and better treatment outcomes.
• Collaborative Research Ventures: The convergence of academic institutions, biotech companies, and healthcare providers is accelerating the pace of biomarker development. These partnerships are focused on translating biologically validated biomarkers into clinical practice, bringing innovations to market faster.
• Focus on Proteomics and Genomics: Proteomic and genomic technologies are playing a central role in the search for brain biomarkers. These techniques are uncovering potential biomarkers that can be used for the early detection and monitoring of neurodegenerative diseases.
• Improved Imaging Modalities: Advances in imaging technologies, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), are enhancing the sensitivity, specificity, and quantification of cerebral biomarkers. These imaging advancements are crucial for better understanding and diagnosing brain diseases.

These recent developments are propelling the brain biomarker market forward, with improvements in analytical capabilities and clinical applications leading to better diagnostic and therapeutic strategies.

Strategic Growth Opportunities for Brain Biomarker Market

Several strategic growth opportunities are emerging within the brain biomarker market, driven by advances in research, technology, and the rising incidence of neurological disorders.

• Alzheimer's Disease Early Diagnosis: The need for early diagnostic tools for Alzheimer's disease is creating significant growth opportunities. Biomarkers can aid in early diagnosis, allowing for timely intervention and improved patient outcomes.
• Advancing Treatment Options: The shift toward personalized medicine is paving the way for biomarker-based therapies. Developing treatments based on specific biomarker profiles will enable more effective and targeted therapies, reducing the risk of side effects.
• Investments in Neurodegenerative Disease Research: Growing concerns about diseases like Parkinson's and multiple sclerosis are driving investments in brain biomarker research. New biomarkers discovered in these areas will aid in diagnosing and monitoring these conditions more effectively.
• Research Collaborations: Increasing collaboration between academia, research organizations, and industry players is accelerating biomarker discovery and application. These partnerships are helping to shorten research timelines and bring new diagnostic tools to market more quickly.
• Expanding Clinical Applications: There is a growing demand for the integration of biomarkers into clinical practice. As biomarkers are validated for broader use, there will be more opportunities to apply them in the diagnosis and management of various neurological diseases.

These opportunities underscore the potential for continued growth in the brain biomarker market, offering avenues for new discoveries and enhanced patient care in the field of neurology.

Brain Biomarker Market Driver and Challenges

The commercialization of brain biomarker products is influenced by a number of drivers and challenges such as available technology, and socio-economic and regulatory environment. It is important to know these dynamics in order to operate in the market.

The factors responsible for driving the brain biomarker market include:

• Technological Advancements: The constant technological improvement of principles, methods, and means of biomarker detection and their analysis is ensuring market growth. Development of new identifiers and diagnostic imagination, genomic and proteomic technologies improves sensitivity and specificity in diagnosis.
• Increased Research Funding: The growth in the investment allocated for neuroscience and neurological disorder studies is promoting the growth of brain biomarkers. Financing of clinical trials is usually heavy, and this subsidizes and hastens the process of verification leading to effective decision-making.
• Rising Incidence of Neurological Disorders: New cases of Alzheimer's and Parkinson's diseases are on the rise which in turn pushes for effective diagnostic solutions. Biomarkers, in such cases, help in clinical detection as well as monitoring of the condition.
• Increasing Demand For Biomarker Based Tests: The increase in the adoption of personalized medicine has seen biomarker based diagnostics become sought after. Oncology as a clinical practice benefits from biomarkers since treatment approaches are catered to the needs of specific patients improving clinical outcomes.
• Jointly Helping To Apply For The Grant: Parallel inventions through effective collaborations with academic, industrial, and clinical partners are supporting brain biomarkers developmental efforts. These cooperative relationships foster resource sharing which helps in speeding up progress.

Challenges in the brain biomarker market are:

• Regulatory Barriers: Obtaining regulatory approval for biomarker-based diagnostic devices can be time-consuming and costly. Slow approval processes can delay the availability of new diagnostic tools to patients in need.
• Financial Barriers: The high costs associated with the development and validation of brain biomarkers pose a challenge, particularly for smaller companies with limited financial resources. This can slow down progress and limit access to innovative solutions.
• Market Competition: The growing number of companies entering the brain biomarker market is intensifying competition. Companies must differentiate their products and services to maintain a competitive edge and capture market share.

Navigating these challenges while capitalizing on market drivers will be key to the success of companies in the brain biomarker space.

List of Brain Biomarker Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies brain biomarker companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the brain biomarker companies profiled in this report include-

• Siemens Healthineers
• Electrical Geodesics
• Lifesign
• Advanced Brain Monitoring
• BrainScope
• GE Healthcare
• Johnson & Johnson
• Natus Medical
• F. Hoffmann-La Roche
• Qiagen

Brain Biomarker by Segment

The study includes a forecast for the global brain biomarker market by product type, disease indication, application, end use, and region.

Brain Biomarker Market by Product Type [Analysis by Value from 2019 to 2031]:

• Biomarker Test Kits
• Biomarker Analyzers

Brain Biomarker Market by Disease Indication [Analysis by Value from 2019 to 2031]:

• Stroke
• MND & ALS
• Alzheimer's Disease & Other Dementias
• Parkinson's Disease
• Huntington's Disease

Brain Biomarker Market by Application [Analysis by Value from 2019 to 2031]:

• Diagnosis
• Drug Discovery and Development
• Others

Brain Biomarker Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Research Laboratories
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Others

Brain Biomarker Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Brain Biomarker Market

The brain biomarker market is growing globally, with key contributions from countries like the United States, China, Germany, India, and Japan. Each of these countries is making strides in the development of brain biomarkers and their clinical applications.

• United States: The U.S. is leading in brain biomarker research and development, particularly in the area of Alzheimer's disease. Recent FDA approvals for blood-based amyloid-beta biomarkers have paved the way for new diagnostic methods. The use of AI in biomarker analysis is also growing, enhancing diagnostic accuracy and speed.
• China: China is investing heavily in brain biomarker research, particularly for neurodegenerative diseases. Collaborations with international institutions are helping to validate biomarkers, and AI integration is improving data analysis capabilities. Rising mental health awareness is driving demand for more biomarker studies.
• Germany: Germany is at the forefront of brain biomarker development, with advancements in imaging technologies and a strong emphasis on clinical implementation. The country is also promoting deeper collaboration between industries and universities to drive innovation.
• India: India's brain biomarker market is expanding due to increased research activities in neurology and psychiatry. Researchers are focusing on low-cost biomarker discovery, which makes the technology more accessible to the local population. The increasing prevalence of neurological diseases is further driving demand.
• Japan: Japan is a leader in integrating AI technologies into brain biomarker research. The country is also advancing the use of biomarkers in clinical trials for neuro-stimulating drugs, improving patient outcomes and treatment efficacy.

Each of these countries is making significant contributions to the development of brain biomarkers, with a focus on improving diagnostic accuracy and therapeutic interventions for neurological diseases.

Features of the Global Brain Biomarker Market

Market Size Estimates: Brain biomarker market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by various segments and regions.

Segmentation Analysis: Brain biomarker market size by various segments, such as by product type, disease indication, application, end use, and region in terms of value ($B).

Regional Analysis: Brain biomarker market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product type, disease indication, application, end use, and regions for the brain biomarker market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the brain biomarker market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the brain biomarker market by product type (biomarker test kits and biomarker analyzers), disease indication (stroke, MND & ALS, Alzheimer's disease & other dementias, Parkinson's disease, and Huntington's disease), application (diagnosis, drug discovery and development, and others), end use (hospitals, research laboratories, ambulatory surgical centers, diagnostic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Brain Biomarker Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Brain Biomarker Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Brain Biomarker Market by Product Type
  • 3.3.1: Biomarker Test Kits
  • 3.3.2: Biomarker Analyzers
• 3.4: Global Brain Biomarker Market by Disease Indication
  • 3.4.1: Stroke
  • 3.4.2: MND & ALS
  • 3.4.3: Alzheimer's Disease & Other Dementias
  • 3.4.4: Parkinson's Disease
  • 3.4.5: Huntington's Disease
• 3.5: Global Brain Biomarker Market by Application
  • 3.5.1: Diagnosis
  • 3.5.2: Drug Discovery and Development
  • 3.5.3: Others
• 3.6: Global Brain Biomarker Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Research Laboratories
  • 3.6.3: Ambulatory Surgical Centers
  • 3.6.4: Diagnostic Laboratories
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Brain Biomarker Market by Region
• 4.2: North American Brain Biomarker Market
  • 4.2.1: North American Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.2.2: North American Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others
• 4.3: European Brain Biomarker Market
  • 4.3.1: European Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.3.2: European Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others
• 4.4: APAC Brain Biomarker Market
  • 4.4.1: APAC Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.4.2: APAC Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others
• 4.5: ROW Brain Biomarker Market
  • 4.5.1: ROW Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.5.2: ROW Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Brain Biomarker Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Brain Biomarker Market by Disease Indication
  • 6.1.3: Growth Opportunities for the Global Brain Biomarker Market by Application
  • 6.1.4: Growth Opportunities for the Global Brain Biomarker Market by End Use
  • 6.1.5: Growth Opportunities for the Global Brain Biomarker Market by Region
• 6.2: Emerging Trends in the Global Brain Biomarker Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Brain Biomarker Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Brain Biomarker Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Siemens Healthineers
• 7.2: Electrical Geodesics
• 7.3: Lifesign
• 7.4: Advanced Brain Monitoring
• 7.5: BrainScope
• 7.6: GE Healthcare
• 7.7: Johnson & Johnson
• 7.8: Natus Medical
• 7.9: F. Hoffmann-La Roche
• 7.10: Qiagen